Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 1980-1984  (4)
  • thromboxane synthetase inhibitors  (2)
  • antiarrhythmic agent  (1)
  • cardiovascular effects  (1)
Source
Material
Years
  • 1980-1984  (4)
Year
Keywords
  • 1
    Electronic Resource
    Electronic Resource
    A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud’s syndrome (1984)
    Springer
    European journal of clinical pharmacology 27 (1984), S. 61-65 
    Details
    ISSN: 1432-1041
    Keywords: thromboxane synthetase inhibitors ; Raynaud’s syndrome ; systemic sclerosis ; UK-38,485 ; ischaemic attacks ; red blood cell rheology
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Ten patients with moderate to severe Raynaud’s syndrome were recruited into a four week randomised double blind crossover study to compare the efficacy of UK-38,485 50 mg, a new thromboxane synthetase inhibitor with that of placebo. With the doses used there was no significant difference between the two treatment periods in the number, severity and duration of ischaemic attacks, the mean hand temperatures, forearm and digital blood flow and red blood cell rheology.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF02395208
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    The effect of a new antiarrhythmic agent, flecainide acetate, on systolic time intervals (1983)
    Springer
    European journal of clinical pharmacology 25 (1983), S. 13-18 
    Details
    ISSN: 1432-1041
    Keywords: flecainide ; antiarrhythmic agent ; systolic time intervals ; heart functions ; conduction delay ; myocardial contractility
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary We investigated the effect of flecainide on systolic time intervals in 6 healthy subjects. A randomized, double blind, cross-over study was designed using flecainide (2 mg/kg), propranolol (0.2 mg/kg) or saline. In comparison with placebo, flecainide increased heart rate, diastolic BP, QT-Index, QS2-Index, PEP, and reduced LVET-Index (p〈0.05). It caused a significant increase in PR interval, QRS duration, and PEP/LVET (p〈0.01). Propranolol, compared with placebo, decreased heart rate and systolic BP (p〈0.05). It increased PR interval, PEP, and PEP/LVET ratio (p〈0.05). In comparison with propranolol, flecainide increased heart rate and QRS duration (p〈0.01, p〈0.001 respectively). It increased diastolic BP, PR interval, QS2-Index, PEP, and PEP/LVET ratio, and decreased LVET-Index (p〈0.05). These changes in STI induced by flecainide may be produced by depression of myocardial contractility. Intraventricular conduction delay may be an additional contributing factor.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00544007
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Preliminary clinical pharmacological studies of S3341, a new hypotensive agent, and comparison with clonidine in normal males (1984)
    Springer
    European journal of clinical pharmacology 27 (1984), S. 281-286 
    Details
    ISSN: 1432-1041
    Keywords: S3341 ; clonidine ; hypotensive drug ; side-effects ; cardiovascular effects ; alpha2-receptor
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary S3341, a new hypotensive agent which binds to alpha2-receptors in animal brain preparations, was studied in normal healthy male volunteers. A dose ranging study with 15 and 25 µg/kg of S3341 was performed in a double blind, placebo controlled randomised and balanced manner with 3 subjects. A decrease or BP without noticeable sedation (assessed by visual analogue scales) was seen. One, 2 mg of S3341, 0.1 and 0.2 mg of clonidine were then compared in a double blind, placebo controlled, randomised and balanced manner in 10 subjects. BP, heart rate, systolic time intervals (STI), critical flicker frequency, choice reaction time, pursuit rotor, stimulated salivary volume, and dryness of mouth and sedation with visual analogue scales, were measured at 0, 1.5, 3.0, 4.5 and 6.0 h after drug administration. The relationship between decreases in BP and sedation was assessed by linear regression analysis, with the former as the independent (predictor) response and the latter as the dependent (response) variate. Both drugs produced a similar decrease of BP which was significantly different from placebo. Changes in psychomotor function tests were not significant. Both drugs produced dryness of mouth and sedation which were significantly different from placebo but changes were less with S3341. Clonidine showed a significantly steeper slope than S3341 in the relationship between decreases in BP and sedation. This must be interpreted with caution as there was wide variation in the correlation between decreases in BP and sedation, but it may be possible to achieve lesser sedation with S3341.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00542160
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome (1984)
    Springer
    European journal of clinical pharmacology 27 (1984), S. 61-65 
    Details
    ISSN: 1432-1041
    Keywords: thromboxane synthetase inhibitors ; Raynaud's syndrome ; systemic sclerosis ; UK-38,485 ; ischaemic attacks ; red blood cell rheology
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Ten patients with moderate to severe Raynaud's syndrome were recruited into a four week randomised double blind crossover study to compare the efficacy of UK-38,485 50 mg, a new thromboxane synthetase inhibitor with that of placebo. With the doses used there was no significant difference between the two treatment periods in the number, severity and duration of ischaemic attacks, the mean hand temperatures, forearm and digital blood flow and red blood cell rheology.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00553156
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...